阅读说明：本技术 一种日本血吸虫病早期诊断尿液生物标志物及筛选方法和应用 (Schistosomiasis japonica early diagnosis urine biomarker and screening method and application thereof ) 是由 吕志跃 胡玥 黄萍 周洪利 马玉斌 于 2019-04-04 设计创作，主要内容包括：本发明公开了一种用于日本血吸虫病早期诊断的尿液生物标志物,所述尿液生物标志物为黄尿酸、萘磺酸或庚酰肉碱中的一种或多种。所述标志物的灵敏度及特异度均大于0.9,曲线下面积(AUC)均大于0.9,表明这三个指标预测性较好,可用于日本血吸虫病早期诊断。本发明还公开了基于代谢组学的日本血吸虫病早期诊断尿液生物标志物的筛选方法,通过构建小鼠日本血吸虫病模型,利用超高效液相色谱-串联质谱技术对小鼠尿液进行代谢组学分析,发现并分析正常小鼠和日本血吸虫感染小鼠之间的特征性差异代谢物,即为日本血吸虫病早期诊断生物标志物。所述筛选方法具有无创、方便快捷的特点,并且能够准确反映日本血吸虫病感染小鼠与正常小鼠的代谢谱差异,特异性高。(The invention discloses a urine biomarker for early diagnosis of schistosomiasis japonica, which is one or more of xanthurenic acid, naphthalenesulfonic acid or heptanoyl carnitine. The sensitivity and specificity of the marker are both greater than 0.9, and the area under the curve (AUC) is both greater than 0.9, which shows that the three indexes are good in predictability and can be used for early diagnosis of schistosomiasis japonica. The invention also discloses a screening method of the schistosomiasis japonica early diagnosis urine biomarker based on metabonomics, which comprises the steps of constructing a mouse schistosomiasis japonica model, carrying out metabonomic analysis on mouse urine by using an ultra performance liquid chromatography-tandem mass spectrometry technology, and finding and analyzing characteristic difference metabolites between a normal mouse and a schistosomiasis japonica infected mouse, namely the schistosomiasis japonica early diagnosis biomarker. The screening method has the characteristics of no wound, convenience and quickness, can accurately reflect the metabolic spectrum difference between the schistosomiasis japonica infected mouse and the normal mouse, and has high specificity.)

1. A urine biomarker for early diagnosis of schistosomiasis japonica, which is one or more of xanthurenic acid, naphthalenesulfonic acid or heptanoyl carnitine.

2. The application of one or more of xanthurenic acid, naphthalenesulfonic acid or heptanoyl carnitine as a biomarker for early diagnosis of urine of schistosomiasis japonica.

3. The use of the diagnostic marker of claim 1 for the preparation of an early diagnostic product for schistosomiasis japonica.

4. An early diagnosis product of schistosomiasis japonica, which is characterized in that whether a subject suffers from schistosomiasis japonica is judged by detecting the concentration change of one or more markers of xanthurenic acid, naphthalenesulfonic acid or heptanoyl carnitine in urine of the subject.

5. An early diagnosis product of schistosomiasis japonica comprising a reagent for detecting the content concentration of one or more markers selected from the group consisting of xanthurenic acid, naphthalenesulfonic acid and heptanoylcarnitine in urine of a subject.

6. A screening method of schistosomiasis japonica early diagnosis urine biomarkers based on metabonomics is characterized in that a mouse schistosomiasis japonica model is constructed, the mouse urine is subjected to metabonomic analysis by using an ultra performance liquid chromatography-tandem mass spectrometry technology, and characteristic difference metabolites between a normal mouse and a schistosomiasis japonica infected mouse are found and analyzed, namely the schistosomiasis japonica early diagnosis biomarkers are obtained.

7. The screening method according to claim 6, wherein the conditions of the ultra performance liquid chromatography-tandem mass spectrometry are as follows: a chromatographic column: waters ACQUITY UPLC C18BEH column (2.1X 100mm, 1.7 μm); liquid chromatography conditions: mobile phase: A-H₂O (0.1% formic acid), B-acetonitrile (0.1% formic acid); flow rate: 0.4mL/min, column temperature: 38 ℃, sample introduction: 0.300 mu L; gradient elution procedure: 3% of B in 0-1.2 min, 3% -45% of B in 1.2-10 min, 45% -98% of B in 10-14 min, 98% of B in 14-16 min and 3% of B in 16.1-19 min;

mass spectrum conditions: nitrogen is used as desolventizing agent and taper hole gas; the capillary voltage is 2.5kV, ESI (electronic spray ionization) ion sources are adopted, the detection modes are MS and MSE, the taper hole voltage is 35kV, the reverse taper hole airflow is 30L/h, the ion source temperature is 110 ℃, the desolvation gas temperature is 350 ℃, and the desolvation gas flow is 700L/h; under the condition that the collision energy is 20-50 eV, the ion scanning time is 0.3s, and the data acquisition range is 50-1200 m/z; the leucine-enkephalin solution, ESI-554.2615m/z, was used for accurate mass determination.

Technical Field

The invention relates to the technical field of biomedicine, and more particularly relates to a schistosomiasis japonica early diagnosis urine biomarker, a screening method and application thereof.

Background

Schistosomiasis japonica, a zoonosis parasitic disease that seriously harms human health and hinders socioeconomic development, is caused by Schistosoma japonicum (Schistosoma japonicum), is widely prevalent in asia, and particularly in china, philippines and indonesia, more than 100 million people are infected with the schistosomiasis japonica, and about 4600 million people are threatened. In China, schistosoma japonicum is mainly popular in the middle and lower reaches of Yangtze river and 12 provinces, cities and autonomous regions in the south of the Yangtze river. After more than 60 years of efforts, the prevention and treatment work of schistosomiasis in China has achieved remarkable results, and the current popular areas are mainly distributed in 4 provinces of Anhui, Hubei, Hunan and Jiangxi, but the task is still arduous to achieve the goal of eliminating schistosomiasis nationwide.

The life history of schistosoma japonicum includes sexual reproduction in the terminal host body of human and several mammals and asexual reproduction in the only intermediate host body of oncomelania, and its development stage is divided into seven: eggs, hair larvae, mother larvae, daughter larvae, cercaria, baby larvae and adults. In the schistosoma japonicum infection stage, cercaria, schistosomulum, adult and ovum all can cause damage to a host, and the main reason of the damage is that antigens released during parasitism induce the immune response of the host, so that a series of complex immunopathological reactions occur, and the main reason of death of the disease is the ovum-induced liver granuloma and the subsequent hepatic fibrosis.

The diagnosis of schistosomiasis japonica at present mainly comprises a direct detection method and an indirect detection method. The former is mainly the etiology examination, namely the examination of the eggs in the excrement under a microscope; the latter includes immunological detection and molecular biological detection, such as detection of antigen or antibody in serum, detection of DNA of Schistosoma japonicum in feces, etc. In addition, imaging methods such as ultrasonic examination (US), Computed Tomography (CT), and Magnetic Resonance Imaging (MRI) can also be used for diagnosis of schistosomiasis japonica. However, the above diagnostic methods are low in either specificity or sensitivity and are not suitable for early diagnosis; therefore, there is a need to find a method for early diagnosis of schistosomiasis japonica.

Metabolomics (metabolomics) is a systematic biology subject developed after genomics and proteomics and related to the types, the quantities and the change rules of small molecular metabolites (molecular weight <1200Da) of a biological system after the biological system is stimulated or disturbed, and the corresponding relation between the metabolites and physiological and pathological changes is searched by analyzing the whole metabolic spectrum of an organism, so that a basis is provided for disease diagnosis and biomarkers (Biomarker) related to diseases are searched. The metabonomics analysis means mainly comprise Nuclear Magnetic Resonance (NMR), gas chromatography-mass spectrometry (GS/MS) coupling technology, liquid chromatography-mass spectrometry (LC/MS) coupling technology and the like, wherein ultra-high performance liquid chromatography-tandem mass spectrometry (UPLC-Q-TOF/MS) technology is taken as an advanced separation analysis technology and is widely applied to the research in the metabonomics field, and the strong analysis capability is known to be one of the best analysis technologies of complex samples. At present, the markers for early diagnosis of schistosomiasis japonica are not abundant enough, and the search for new diagnostic markers as far as possible is helpful for the development of early diagnosis of schistosomiasis japonica.

Disclosure of Invention

The invention aims to overcome the defects in the prior art and provide a urine biomarker for early diagnosis of schistosomiasis japonica.

The invention also aims to provide a screening method of the schistosomiasis japonica early diagnosis urine biomarker based on metabonomics.

The invention also aims to provide the application of the schistosomiasis japonica early diagnosis urine biomarker.

The above object of the present invention is achieved by the following technical solutions:

a urine biomarker for early diagnosis of schistosomiasis japonica, wherein the urine biomarker is one or more of xanthurenic acid, naphthalenesulfonic acid or heptanoyl carnitine.

The invention researches and analyzes characteristic differential metabolites between a normal mouse and a schistosoma japonicum infected mouse based on metabonomics, finally obtains one or more of schistosomiasis japonica early diagnosis urine biomarkers-xanthurenic acid, naphthalenesulfonic acid or heptanoyl carnitine based on the metabonomics, wherein the sensitivity and specificity of the markers are both more than 0.9, and the area under the curve (AUC) is both more than 0.9, thereby prompting that the three indexes have good predictability and can be used for the early diagnosis of schistosomiasis japonica.

The application of one or more of xanthurenic acid, naphthalenesulfonic acid or heptanoyl carnitine as a biomarker for early diagnosis of urine of schistosomiasis japonica.

The invention also requests to protect the application of the urine biomarker in the preparation of schistosomiasis japonica early diagnosis products; the urine biomarker is applied to the preparation and screening of schistosomiasis japonica drugs.

An early diagnosis product for schistosomiasis japonica, which determines whether a subject suffers from schistosomiasis japonica by detecting a change in concentration of one or more markers of xanthurenic acid, naphthalenesulfonic acid, or heptanoylcarnitine in urine of the subject.

An early diagnosis product for schistosomiasis japonica comprises a reagent for detecting the content concentration of one or more markers in the urine of a subject, such as xanthurenic acid, naphthalenesulfonic acid or heptanoyl carnitine.

The invention also provides a screening method of the schistosomiasis japonica early diagnosis urine biomarker based on metabonomics, which constructs a mouse schistosomiasis japonica model, utilizes the ultra performance liquid chromatography-tandem mass spectrometry technology to carry out metabonomic analysis on mouse urine, finds and analyzes characteristic difference metabolites between a normal mouse and a schistosomiasis japonica infected mouse, and the metabolite is the schistosomiasis japonica early diagnosis biomarker.

As a preferred embodiment, the screening method for schistosomiasis japonica early diagnosis urine biomarkers based on metabonomics specifically comprises the following steps:

(1) healthy mice were divided into seven experimental groups: normal control group, group for 3 days of Schistosoma japonicum infection, group for 7 days of Schistosoma japonicum infection, group for 14 days of Schistosoma japonicum infection, group for 21 days of Schistosoma japonicum infection, group for 28 days of Schistosoma japonicum infection and group for 42 days of Schistosoma japonicum infection; the normal control group is not treated, and the mice in the infected group are attached with a coverslip stained with cercaria to infect the schistosoma japonicum through the abdominal skin;

(2) urine samples of seven experimental mice were collected using metabolic cages, respectively, and ultrapure water 1: diluting with 10, centrifuging at 4 deg.C for 10min at 10000g, and collecting supernatant to obtain test solution;

(3) detecting the test solution by using ultra-high performance liquid chromatography-tandem mass spectrometry to obtain the fingerprint of the urine samples of the mice in the seven experimental groups;

(4) and finally obtaining the schistosomiasis japonica early diagnosis urine marker based on metabonomics by preprocessing data, performing multivariate statistical analysis and screening differential metabolites, and comparing the accurate molecular weights of the differential metabolites with a network database.

Preferably, the conditions of the liquid chromatography in the ultra performance liquid chromatography-tandem mass spectrometry are as follows: a chromatographic column: WatersACQUITY UPLC C18BEH column (2.1X 100mm, 1.7 μm); liquid chromatography conditions: mobile phase: A-H₂O (0.1% formic acid), B-acetonitrile (0.1% formic acid); flow rate: 0.4mL/min, column temperature: 38 ℃, sample introduction: 0.300 mu L; gradient elution procedure: 3 percent of B in 0-1.2 min, 3-45 percent of B in 1.2-10 min, 45-98 percent of B in 10-14 min, 98 percent of B in 14-16 min and 3 percent of B in 16.1-19 min.

Mass spectrum conditions: nitrogen is used as desolventizing agent and taper hole gas; the capillary voltage is 2.5kV, ESI (electronic spray ionization) ion sources are adopted, the detection modes are MS and MSE, the taper hole voltage is 35kV, the reverse taper hole airflow is 30L/h, the ion source temperature is 110 ℃, the desolvation gas temperature is 350 ℃, and the desolvation gas flow is 700L/h; under the condition that the collision energy is 20-50 eV, the ion scanning time is 0.3s, and the data acquisition range is 50-1200 m/z; the leucine-enkephalin solution, ESI-554.2615m/z, was used for accurate mass determination.

Compared with the prior art, the invention has the following beneficial effects:

(1) the invention provides a urine biomarker for early diagnosis of schistosomiasis japonica, which is one or more of xanthurenic acid, naphthalenesulfonic acid or heptanoyl carnitine, wherein the sensitivity and specificity of the marker are both greater than 0.9, and the area under the curve (AUC) is both greater than 0.9, so that the three indexes are good in predictability and can be used for early diagnosis of schistosomiasis japonica.

(2) The invention carries out metabonomics analysis on mouse urine by an ultra-high performance liquid chromatography-tandem mass spectrometry technology, and carries out model construction and discriminant analysis on response intensity data of substance peaks in all samples, thereby finding out characteristic differential metabolites between a normal mouse and a schistosoma japonicum infected mouse, further analyzing content change of the characteristic differential metabolites, and finding out specific differential metabolites caused by schistosomiasis japonica, namely early diagnosis molecular markers of schistosomiasis japonica. The method provided by the invention has the characteristics of no wound, convenience and quickness, can accurately reflect the metabolic spectrum difference between the schistosomiasis japonica infected mouse and the normal mouse, and has high specificity.

Drawings

Fig. 1 is a Base Peak Intensity (BPI) chromatogram of seven experimental groups in positive ion mode.

Fig. 2 is a Base Peak Intensity (BPI) chromatogram for seven experimental groups in negative ion mode.

FIG. 3 is a graph of the scores of PCA and PLS-DA in the positive and negative ion mode for seven experimental groups; (A) PCA score plot in positive ion mode; (B) PCA score plot in negative ion mode; (C) PLS-DA score plot in positive ion mode; (D) PLS-DA score plot in negative ion mode.

FIG. 4 is a plot of OPLS-DA scores and S-plot for seven experimental groups in positive ion mode.

FIG. 5 is the OPLS-DA score plot and S-plot for seven experimental groups in negative ion mode.

Fig. 6 is the abundance of the three urine biomarkers in seven experimental groups (a) and the corresponding ROC curves (B).

Detailed Description

The invention is further described with reference to the drawings and the following detailed description, which are not intended to limit the invention in any way. Reagents, methods and apparatus used in the present invention are conventional in the art unless otherwise indicated.

Unless otherwise indicated, reagents and materials used in the following examples are commercially available.